Evidence map›Paper›PMID 40154213›Full record

SynthesisEuropean journal of cancer (Oxford, England : 1990)2025

Unraveling the clinical impact of differential DNA methylation in PDAC: A systematic review.

Julia Adriana Kasmirski, Raj Roy, Christopher Wu, Lauren Wheeler, K Kerrick Akinola, Herbert Chen, J Bart Rose, Changde Cheng, Smita Bhatia, Andrea Gillis

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in European journal of cancer (Oxford, England : 1990), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Julia Adriana KasmirskiDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Raj RoyDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Christopher WuDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Lauren WheelerDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
K Kerrick AkinolaDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Herbert ChenDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
J Bart RoseDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Changde ChengDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Smita BhatiaDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Andrea GillisDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: agillis@uabmc.edu.

Funding

TRAINING AND CAREER DEVELOPMENTU54CA118948 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2005 to 2025
$2.4M
Surgical Oncology Research Training ProgramT32CA229102 · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2025 to 2025
$456k
NCI NIH HHS L60 CA294405NCI NIH HHS T32 CA229102NCI NIH HHS U54 CA118948
6 · The paper itself

Abstract

introductionDespite significant efforts to improve clinical outcomes, pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate. The poor prognosis associated with this disease is multifactorial and associated with a highly variable genetic profile associated with its pathogenesis. Epigenetic modifications including DNA methylation further affect the expression of genetic material. However, there is no comprehensive understanding of the clinical impact of DNA methylation in PDAC.

methodsA systematic literature review was registered on the International Prospective Register of Systematic Reviews database (CRD42023451955) and followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. An electronic search was conducted using the following databases: CINAHL Plus, Cochrane Library, Embase, Web of Science, Ovid Medline, and Google Scholar. Inclusion criteria included studies of patients with a PDAC diagnosis and information regarding genes or CpG sites that potentially affect diagnosis, prognosis, or survival of PDAC.

resultsThe initial search retrieved 2402 articles, and 423 duplicates were excluded. After exclusion criteria was applied, 19 studies were included. The most common genes recorded as affecting tumor pathogenesis were SFRP1 (n = 3/19, 15.7 %) and NPTX2 (n = 2/19, 10,5 %). Studies indicated that hypermethylation of SFRP1 and NPTX2 were associated with poor prognosis.

conclusionsPDAC is associated with a range of epigenetic modifications. Methylation of specific genes related to PDAC may influence survival and prognosis and be a therapeutic target. Individual patient epigenetic analysis may be a future direction in directing PDAC treatment and prognosis.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalDNA MethylationPancreatic NeoplasmsEpigenesis, GeneticHumansPrognosisBiomarkers, TumorEpigeneticsMethylationPancreatic cancerPDAC

Identifiers

PMID40154213
PMCPMC12344563

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.